Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT03770052

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03770052
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03770052. Randomized; double masking; primary purpose treatment. Start 2018-10-24 (actual); primary completion 2021-08-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
Condition
Type 2 Diabetes Mellitus
Condition
Inadequate Glucose Control
Intervention (Drug)
duvie
Lead sponsor
Pusan National University Hospital (class: other)
Collaborator
Chong Kun Dang Pharmaceutical Corp. (class: industry)

Record details

Record id
cardio:ct-nct03770052
Content hash
5a091ef0624a6d41a6cb9be47c51767171e63d25ac9bf5d7e2ea6ea0520cb7d2